Description
Bio-Rad Laboratories Just Supercharged Its PCR Portfolio—Is This a Game-Changer in Oncology?
Bio-Rad Laboratories’ financial performance for the third quarter of 2025 was characterized by modest revenue growth, constrained by headwinds in various segments. The company reported net sales of approximately $653 million, a slight increase from $650 million in the third quarter of 2024 on a reported basis but a 1.7% decrease on a currency-neutral basis. This outcome was primarily influenced by challenges in the academic research and biotech funding sectors, which impacted the Life Science segment. In the Life Science division, sales remained flat year-over-year at $262 million, largely due to ongoing funding constraints within the academic and biotech markets. Positive developments included robust performance in the process chromatography business, which experienced double-digit growth as a result of customer order timing. However, this was not enough to counterbalance the overall softness in instrument demand and consumables.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
